1. Home
  2. ZVIA vs HURA Comparison

ZVIA vs HURA Comparison

Compare ZVIA & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zevia PBC

ZVIA

Zevia PBC

N/A

Current Price

$0.94

Market Cap

126.3M

ML Signal

N/A

Logo TuHURA Biosciences Inc.

HURA

TuHURA Biosciences Inc.

N/A

Current Price

$1.39

Market Cap

123.0M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ZVIA
HURA
Founded
2007
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Beverages (Production/Distribution)
Sector
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
126.3M
123.0M
IPO Year
2021
2010

Fundamental Metrics

Financial Performance
Metric
ZVIA
HURA
Price
$0.94
$1.39
Analyst Decision
Strong Buy
Buy
Analyst Count
6
4
Target Price
$3.67
★ $8.04
AVG Volume (30 Days)
451.5K
★ 547.2K
Earning Date
11-04-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 55.88
47.93
EPS
★ N/A
N/A
Revenue
★ $161,259,000.00
N/A
Revenue This Year
$9.55
N/A
Revenue Next Year
$6.45
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 4.01
N/A
52 Week Low
$0.96
$0.41
52 Week High
$2.75
$3.43

Technical Indicators

Market Signals
Indicator
ZVIA
HURA
Relative Strength Index (RSI) 36.32 34.08
Support Level N/A $1.27
Resistance Level $1.52 $2.22
Average True Range (ATR) 0.13 0.16
MACD -0.03 -0.03
Stochastic Oscillator 0.53 15.86

Price Performance

Historical Comparison
ZVIA
HURA

About ZVIA Zevia PBC

Zevia PBC is a beverage company disrupting the liquid refreshment beverage industry through refreshing, zero-calorie, zero-sugar, naturally sweetened beverages that are all Non-GMO Project Verified. It offers a platform of products that include a variety of flavors across Soda, Energy Drinks, Organic Tea, Mixers, Kidz drinks, and Sparkling Water. Its products are distributed across the U.S. and Canada through a network of retailers in the food, drug, mass, natural, and e-commerce channels. The company derives a majority of its revenue from the United States.

About HURA TuHURA Biosciences Inc.

TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.

Share on Social Networks: